IMAGE: This photo shows SLU researchers Ian Miller, Konstantin Malley and Sergey Korolev, Ph.D. view more
Credit: Saint Louis University / Ellen Hutti.
ST. LOUIS — In a recent paper published in Nature Communications, Saint Louis University scientists report that they have determined the structure of a key protein that is involved in the body’s inflammatory response. This finding opens the door to developing new treatments for a wide range of illnesses, from heart disease, diabetes and cancer to neurodegenerative disorders, including Parkinson’s disease.
Sergey Korolev, Ph.D., associate professor of biochemistry and molecular biology at SLU, studies protein structures at the atomic resolution level to understand mechanism of their function in the body.
Korolev and his team examined a long-studied but little-understood enzyme, calcium-independent phospholipase A2β, (iPLA2β) that cleaves phospholipids in membrane. It produces important signals after injury to initiate the inflammatory response. The team wanted to know how the enzyme is activated during injury, how it hydrolyses substrates and how it gets shut down, turning the inflammatory response off.
Korolev says that the protein kept popping up in seemingly unrelated areas of study throughout the last few decades.
“It was first discovered more than 20 years ago at Washington University in Richard Gross’s lab,” Korolev
Article originally posted at